bml 190 has been researched along with Adjuvant Arthritis in 1 studies
indomethacin morpholinylamide: an inverse agonist of the cannabinoid CB2 receptor
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, L | 1 |
| Zhang, X | 1 |
| Wu, P | 1 |
| Li, H | 1 |
| Jin, S | 1 |
| Zhou, X | 1 |
| Li, Y | 1 |
| Ye, D | 1 |
| Chen, B | 1 |
| Wan, J | 1 |
1 other study available for bml 190 and Adjuvant Arthritis
| Article | Year |
|---|---|
BML-111, a lipoxin receptor agonist, modulates the immune response and reduces the severity of collagen-induced arthritis.
Topics: Animals; Ankle Joint; Arthritis, Experimental; Cell Proliferation; Collagen Type II; Disease Models, | 2008 |